Giulia Viale

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment.

Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment.

Journal: Frontiers in oncology

Published: April 01, 2026

[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.

[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.

Journal: Breast (Edinburgh, Scotland)

Published: February 11, 2026

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Journal: NPJ precision oncology

Published: February 03, 2026

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.

Journal: Cancer treatment reviews

Published: December 05, 2025

Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209].

Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209].

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 29, 2025

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Journal: NPJ breast cancer

Published: June 29, 2025

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Journal: Cancer treatment reviews

Published: April 24, 2025

Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.

Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 22, 2025

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Journal: JAMA network open

Published: February 21, 2025

From intrinsic to adaptive clusters in breast cancer.

From intrinsic to adaptive clusters in breast cancer.

Journal: Cancer cell

Published: December 19, 2024

Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023.

Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023.

Journal: JAMA network open

Published: July 19, 2024

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

Journal: Frontiers in oncology

Published: January 22, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026